SCHEMBL16570523

SCHEMBL16570523

Cc1nn(Cc2cccnc2N(C)S(C)(=O)=O)c2cc(Nc3ccc4c(c3)CCC(=O)N4)ncc12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTK2 Q05397 17/20 0.58
▸ PTK2B Q14289 7/20 0.58
▸ JAK2 O60674 3/20 0.50
▸ JAK3 P52333 3/20 0.50
▸ AURKA O14965 2/20 0.50
▸ SRPK1 Q96SB4 2/20 0.50
▸ PLK4 O00444 1/20 0.50
▸ PDPK1 O15530 1/20 0.50
▸ DAPK3 O43293 1/20 0.50
▸ ROCK2 O75116 1/20 0.50
▸ STK16 O75716 1/20 0.50
▸ PRKD3 O94806 1/20 0.50
▸ MAP4K4 O95819 1/20 0.50
▸ PAK4 O96013 1/20 0.50
▸ CHEK2 O96017 1/20 0.50
▸ NTRK1 P04629 1/20 0.50
▸ PRKCG P05129 1/20 0.50
▸ INSR P06213 1/20 0.50
▸ LCK P06239 1/20 0.50
▸ FYN P06241 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16570278 0.87 PTK2 (0.59) PTK2PTK2BJAK2JAK3AURKA
SCHEMBL16570772 0.84 PTK2 (0.59) PTK2PTK2BJAK2JAK3AURKA
SCHEMBL16570416 0.81 PTK2 (0.48) PTK2PTK2BJAK2JAK3
SCHEMBL16570767 0.80 PTK2 (0.49) PTK2JAK2JAK3
SCHEMBL16569967 0.79 PTK2 (0.66) PTK2PTK2BJAK2JAK3AURKA
SCHEMBL16570835 0.79 KIF11 (0.42) PTK2PTK2BMAPK1KIF11
SCHEMBL16570157 0.78 PTK2 (0.50) PTK2PTK2BSRPK1SRPK2
SCHEMBL16571131 0.77 PTK2 (0.66) PTK2PTK2BJAK2JAK3AURKA
SCHEMBL16570604 0.76 PTK2 (0.50) PTK2PTK2BJAK2JAK3AURKA
SCHEMBL16570750 0.76 PTK2 (0.66) PTK2PTK2BJAK2JAK3AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2016-08-04 — — US claimed
WO-2015038417-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2015-03-19 — — WO claimed
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2016-08-04 — — US disclosed
WO-2015038417-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2015-03-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS SRC, PTK2, FYN PTK2 2/4885PTK2B 13/4885JAK2 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback